definiens: means, in respect of BPD, QL T, in respect of 2nPc, [COMPANY], in respect of any Additional Photosensitizer, the party giving notice of a right of first refusal in accordance with Section 13.1 ; 1.1.21 means the effective date of the Co - Development Agreement which is July 1, 1994 ;, 1.1.22 has the meaning set out in Section 27.2 ; 1.1.23 has the meaning set out in Section 27.3.2 ; 1.1.24 means any usage of PDT for the treatment, diagnosis or prevention of ophthalmologic conditions, including but not limited to, age - related macular degeneration ( ), diabetic retinopathy, corneal neovascularization, ocular tumours and epithelial overgrowth following cataract surgery ( secondary cataracts ) ; 1.1.25 has the meaning set out in Section 15.2 ; 1.1.26 means the plan approved by the JCC for all Development, which shall include each Development Program approved by the JCC and estimates of all Development Expenses of all such activities of the parties through to commercialization contemplated by this Agreement and shall include all appropriate measures to protect against potential cross - sales identified by the JCC as a condition of such Development prior to the Restatement Date ; 1.1.27 means the Global Development Plan to be approved by the JCC on or before December 31, 1995 as provided in Section 3.3 ; 1.1.28 or means the committee consisting of three senior personnel from each ofQLT and [COMPANY] established pursuant to Section 5 ; 1.1.29 means all Patents having claims reading on Products or portions thereof, or methods of manufacture or use thereof, and claiming an invention conceived jointly by employees, agents or licensors of both [COMPANY] and [COMPANY] during the term of this Agreement applicable to both BPD and 2nPc, including any continuations, continuations in part, divisions, reissues and reexaminations thereof ( including without limitation those listed on Schedule 1.1.29 ) ; 1.1.30 means ( a ) ideas, discoveries, inventions, improvements, technology or trade secrets, ( b ) pharmaceutical, chemical and biological materials, products, components or compositions, ( c ) tests, assays, techniques, regulatory requirements and strategies, data ( including non - clinical and clinical data ), methods, procedures, formulas or processes, ( d ) technical and non - technical data and other information relating to any of the foregoing, ( e ) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating to such information or materials, and ( f ) business processes, price data and ( * 1 Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission . Confidential treatment has been requested with respect to the omitted portions